Asia Healthcare Blog
Exploring the Intersection of Business, Policy and Culture, in the Asian Healthcare Space



Business & Investment

December 14, 2012

Away On Holiday

More articles by »
Written by: Benjamin
Tags: China Economic Observer, , , china telemedicine, contextChina, , Forbes China,
china_holiday

For the next week I will be away on holiday, but in my absence wanted to share some recent work that should be of interest to readers of AsiaHealthcareBlog.  We have some exciting plans in store for the platform which we are eager to share with our reading community.  Look for content expansion and new platform features early in 2013.  In the mean time, some additional information for your reading and – in one case – listening pleasure.

China Economic Observer - “Podcast: Investing in China’s Aging Population … China’s massive population bulge that emerged under Mao and ended with the one-child policy is getting old. People over 60 years old currently make up about 13 percent of China’s population. That number is expected to double in the next 20 years and triple in the next 40. This rapidly aging population presents many challenges that require both government and business to pick up the slack.”

contextChina – a series that will cover China’s healthcare reforms, and the opportunities it will create for investors, operators, and life science companies.  The first piece introducing the topic is here, and the second detailing which sectors appear most attractive today can be read here.

Forbes China – my ongoing healthcare column at Forbes has most recently discussed in more detail the question of what sort of products and enabling technologies might China deploy first, or with a larger base of customers, than in the US, and what sort of gains that could create for the Chinese healthcare system.

China Law Blog – the always useful CLB has a post up introducing a topic we’ll be writing about more here in the coming weeks, specifically the issues that a company must wrestle with when the consider deploying their healthcare business in China.  The slide deck references will be available here shortly along with some narrative to explain the thinking that goes into a coherent and holistic appraisal of what is required to operate profitably and sustainably in China.



About the Author

Benjamin
Ben is the Founder and Managing Director of Rubicon Strategy Group, a consulting firm specializing in helping American and European companies enter emerging markets. He is a member of the National Committee on US-China Relations and holds an advisory board seat at Indiana University’s Research Center on Chinese Politics and Business. He is a columnist for the Asia Times on US-China trade and economic policy matters, with a particular focus on how relations between the two countries are being impacted post the 2008 financial crisis. As a founder of the consulting firm Teleos, he was an early advocate for Chinese companies moving away from cost-only business models towards ones that emphasized brand building, innovation and product development. He founded Teleos Healthcare which licensed, capitalized and commercialized the IP for an OTC medical appliance used to help stop nosebleeds. This company successfully partnered with a major US pharmaceutical company on the product launch for the hemophilia and VWD bleeding disorder community. In addition, Ben has successfully managed projects in China across a number of industries, ranging from consumer goods to more complex engineered products. He holds his MBA from Duke University in Durham, North Carolina.
  •  




0 Comments


Be the first to comment!


Leave a Reply